Sugi Predict

Sugi Predict / Targets / DAPK2

DAPK2

Death-associated protein kinase 2 · Q9UIK4 · DAPK2 on Sugi Atlas →

2,393 patent compounds predicted against DAPK2, 2,122 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8125901 SCHEMBL8125901 0.69 2/20
SCHEMBL2757865 SCHEMBL2757865 0.69 2/20
SCHEMBL6959160 SCHEMBL6959160 0.69 2/20
SCHEMBL6616173 SCHEMBL6616173 0.61 2/20
SCHEMBL6804084 SCHEMBL6804084 0.61 2/20
SCHEMBL6964444 SCHEMBL6964444 0.60 2/20
SCHEMBL6964449 SCHEMBL6964449 0.60 2/20
SCHEMBL6970041 SCHEMBL6970041 0.60 2/20
SCHEMBL6970044 SCHEMBL6970044 0.60 2/20
SCHEMBL5707814 SCHEMBL5707814 0.58 2/20
SCHEMBL6614015 SCHEMBL6614015 0.58 2/20
SCHEMBL6808883 SCHEMBL6808883 0.58 2/20
SCHEMBL4256999 SCHEMBL4256999 0.56 2/20
SCHEMBL4257003 SCHEMBL4257003 0.56 2/20
SCHEMBL9204460 SCHEMBL9204460 0.54 2/20
Sulfurein Sulfurein (SCHEMBL2817568) 0.53 2/20
SCHEMBL3045002 SCHEMBL3045002 0.48 2/20
SCHEMBL3045006 SCHEMBL3045006 0.48 2/20
SCHEMBL6449516 SCHEMBL6449516 0.48 2/20
SCHEMBL3042766 SCHEMBL3042766 0.46 2/20

Clinical trials — most relevant to DAPK2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Minocycline for the Treatment of Early-Phase Schizophrenia PHASE3COMPLETED
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients PHASE3ACTIVE_NOT_RECRUITING
Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity PHASE2RECRUITING
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer PHASE1/PHASE2COMPLETED
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas PHASE1/PHASE2COMPLETED
Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers PHASE1/PHASE2UNKNOWN
Baricitinib Compared to Standard Therapy in Patients With COVID-19 PHASE2UNKNOWN
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer PHASE1UNKNOWN
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy PHASE1UNKNOWN
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Pulsed Electro Magnetic Fields (PEMF) in Depression nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Toward Molecular Profiling of Parkinson's Disease in Easily Accessible Biological Matrices nanACTIVE_NOT_RECRUITING
Autophagy, Oxidative Stress and Hippo Signaling in Human Aortic Aneurysm nanCOMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage nanCOMPLETED
Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients nanNOT_YET_RECRUITING
Immune Cell Response to Stimuli nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a DAPK2 binder may also engage these)

ProteinNameSimilarity
Q8VDF3 — 1.000 Q8VDF3 →
Q869W6 — 0.992 Q869W6 →
Q6PFQ0 — 0.991 Q6PFQ0 →
Q6GLS4 — 0.991 Q6GLS4 →
CAMK2D Calcium/calmodulin-dependent protein kinase type II subunit delta 0.990 landscape →
Q2HJF7 — 0.990 Q2HJF7 →
Q6DEH3 — 0.990 Q6DEH3 →
P11730 — 0.989 P11730 →
P10665 — 0.988 P10665 →
RPS6KA3 Ribosomal protein S6 kinase alpha-3 0.988 landscape →
P18654 — 0.988 P18654 →
Q6PHZ2 — 0.988 Q6PHZ2 →
Q95266 — 0.988 Q95266 →
RPS6KA1 Ribosomal protein S6 kinase alpha-1 0.988 landscape →
Q9DG02 — 0.987 Q9DG02 →
Q8BHI9 — 0.987 Q8BHI9 →
Q63531 — 0.987 Q63531 →
Q5ZKI0 — 0.987 Q5ZKI0 →
P09215 — 0.987 P09215 →
DAPK1 Death-associated protein kinase 1 0.987 landscape →
Q80YE7 — 0.987 Q80YE7 →
CAMK1D Calcium/calmodulin-dependent protein kinase type 1D 0.987 landscape →
Q384J7 — 0.987 Q384J7 →
O08875 — 0.987 O08875 →
PRKCD Protein kinase C delta type 0.987 landscape →
RPS6KA2 Ribosomal protein S6 kinase alpha-2 0.987 landscape →
Q9M101 — 0.987 Q9M101 →
Q9Y899 — 0.987 Q9Y899 →
Q8RWL2 — 0.987 Q8RWL2 →
Q54SJ5 — 0.986 Q54SJ5 →